124 related articles for article (PubMed ID: 23539641)
21. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
24. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
[TBL] [Abstract][Full Text] [Related]
25. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
29. Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.
Trist DG; Ratti E; Bye A
J Recept Signal Transduct Res; 2013 Dec; 33(6):333-7. PubMed ID: 24106886
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Katona C; Hansen T; Olsen CK
Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
[TBL] [Abstract][Full Text] [Related]
31. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
32. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
33. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
McIntyre RS; Fayyad R; Mackell JA; Boucher M
Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
[TBL] [Abstract][Full Text] [Related]
34. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
[TBL] [Abstract][Full Text] [Related]
35. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
[TBL] [Abstract][Full Text] [Related]
36. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
37. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
40. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
